BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

MicrobioTx unveils first fingerprick-based test to profile gut microbiome

06 November 2024 | News

MicrobioTx has ambitious plans in the microbiome space, to extend their offerings for multiple disease conditions and different microbiome sites



Bengaluru-based startup MicrobioTx, a new-age gut microbiome company, has announced the commercial availability of Gut Function Test (GFT) that profiles gut microbiome with just a few blood drops.

With this test, gut microbiome profiling, which was earlier only possible by stool sample, will now be possible with a finger-prick without the need of collecting stool sample. MicrobioTx's GFT is clinically validated in trials at leading Indian research institutes and has been recently approved by the Indian regulator. The commercial launch of the MicrobioTx's GFT is supported by a grant from DPIIT through the Institute of Life Science, Bhubaneshwar.

Scientific evidence has established that a good gut microbiome could set the foundation for good health, such as better weight management, stronger immunity, and other physiological functions. This breakthrough test solution, developed after three years of intense research, allows users to gain valuable insights into their gut health at a fraction of the cost, making it a smart and affordable choice for everyone.

MicrobioTx's GFT test is also complemented by consultation, food recommendations, and Personal ProbioTx, a probiotic that is completely customised based on a user's gut profile. This allows users not just to know their gut profile but also take personalised actions to address their gut health.

Akanksha Gupta, co-founder, MicrobioTx, commented,"We have taken a data-driven approach to develop an artificial intelligence (AI) based model to profile the gut microbiome. While stool based tests to profile gut microbiome have existed for many years, only a small number of gut health enthusiasts undergo these tests. The inconvenience of collecting stool samples, long turn-around time, and prohibitive cost of the test are seen as some of the reasons. However, the test launched today could change it all".